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Dengue disease is the most rapidly spreading mosquito-borne
iral disease. Worldwide, between 2.5 and 3.6 billion people, over
0% of the population, are at risk, in over 100 endemic countries. An
stimated 50 to 100 million dengue infections occur every year, of
hich 2 million cases evolve to severe Dengue Hemorrhagic Fever,
nd 21 000 would result in death. Most severe disease and deaths
ccur in children. The rapid global spread of dengue is due to: 1)
emographic changes (i.e., population growth and land use pat-
erns); 2) increased urban population size and density due to rural
o urbanmigration 3)modern transportationwith increasedmove-
ent of people, commodities, animals, vectors and pathogens; and
) changes in public health policies and infrastructure among other
hings.
The geographic spread of both the mosquito vectors and the
iruses has led to a global resurgence of epidemic dengue disease
nd emergence of severe forms in the past 25 years. Dengue is
ow endemic in Asia, the Paciﬁc area, Africa, some parts of US (e.g.
uerto Rico), and Latin America (including the Caribbean). South-
ast Asia and the Western Paciﬁc Regions bear nearly 75% of the
engue global disease burden. In 2010, 187,333 dengue cases were
eported to the WHO SEA ofﬁce; and 354,009 cases were reported
o the WHO Western Paciﬁc Region. Efforts to control the vector
ave limited effect on the risk for disease in humans.
While geographical expansion of dengue and its vector are
vident, the true burden of disease is underestimated due to con-
traints inherent to public health surveillance systems and the
hallenges speciﬁc to dengue.
In the absence of an effective vaccine, public health systems
ocus on the early identiﬁcation and early response to outbreaks.
owever, once adiseasebecomesvaccinepreventable, surveillance
ystems become key tools to assess the performance of vaccination
rograms and need to be optimized to suit that purpose.
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The WHO estimates that approximately 1.8 billion individuals
living in Southeast Asia andWestern Paciﬁc are at risk of dengue, ie,
nearly 75% of the current global dengue burden. Without anti-viral
drugs and vaccines, vector control has been the mainstay of pre-
vention against dengue. Resource-limited areas lacking sustainable
resources to combat the vector are badly hit by the rising number
of dengue cases.
It is worth noting that there are several studies in recently years
addressing dengue disease burden in anticipation of an approved
and available vaccine in the near future. A study conducted in 2005
suggested that the cost of dengue in 8 countries in the Americas
and Asia was at least 587 million international dollars. Adjusted for
under-reporting, the amount could rise to 1.8 billion international
dollars. A comprehensive systematic review and expert opinions
underlined the difﬁculties in estimating disease burden across the
globe and in different period of assessment such as using only DHF
incidence inestimatingDALY in theearlier studies, under-reporting
of non-hospitalized dengue fever cases, the inconsistent applica-
tion of disability score, etc. Recommendation was made to study
cost-effectiveness to avoid the inherent difﬁculties of cost-beneﬁt
analyses requiring conversion of beneﬁts into monetary units.
A study was done recently in Singapore to look at the economic
impact of dengue illness and the cost-effectiveness of future vac-
cination program. Singapore is a well developed city island state
located centrally in Southeast Asia, a dengue high burden region.
Paradoxical to the decline of vector density as a result of the inter-
nationally well-recognized vector control program, the country
experienced resurgent of dengue epidemics and on-going dengue
transmission. The study estimated an average economic impact of
dengue illness from 2000-2009 ranging between US$0.85 billion
and 1.15 billion, of which control costs constituted 42%-59%.
The substantial cost of dengue illness and prevention indicateshttp://dx.doi.org/10.1016/j.ijid.2012.05.015
